<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Adult naive T cells, which are at rest in normal conditions, could have proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Adult naive T cells, which are at rest in normal conditions, could have proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Adult naive T cells, which are at rest in normal conditions, might have proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Adult naive T cells, which are at rest in normal conditions, might have strongly proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients are able to be found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Our observations illustrate that the human placenta has been endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Our observations illustrate that the human placenta has been endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Stat5ab-/-peripheral T cells have regained the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>The ability of EBD cells having strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>The ability of EBD cells having the ability to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>The ability of EBD cells that is able to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>These results show that intrasplenically transplanted fetal liver cells will proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Adult naive T cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult naive T cells have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult naive T cells may have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Adult naive T cells regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Adult naive T cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Adult naive T cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>EBD cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>EBD cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>EBD cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>EBD cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Further, HSC are able to be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>HIV-specific CD4+ T cells of viremic patients are observed to regain the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>HIV-specific CD4+ T cells of viremic patients can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>HIV-specific CD4+ T cells of viremic patients may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, could have proliferated strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, could have proliferated strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, will strongly proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>HSC are observed to regain the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>HSC may have regained the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>HSC, which are at rest in normal conditions, could have strongly proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>HSC, which are at rest in normal conditions, will strongly proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Our observations illustrate that Adult naive T cells can be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Our observations illustrate that Adult naive T cells is able to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Our observations illustrate that Adult naive T cells may have been endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Our observations illustrate that Adult naive T cells will be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Our observations illustrate that HSC has the ability to be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has the ability to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Our observations illustrate that endothelial cells may have been endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Stat5ab-/-peripheral T cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Stat5ab-/-peripheral T cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>endothelial cells have the probability of regaining the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>endothelial cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>endothelial cells regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>endothelial cells regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>endothelial cells, which are at rest in normal conditions, proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>the human placenta are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>the human placenta may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>the human placenta may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>the human placenta, which are at rest in normal conditions, might have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>intrasplenically transplanted fetal liver cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>intrasplenically transplanted fetal liver cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
